Page 1156 - Williams Hematology ( PDFDrive )

1130 Part VIII: Monocytes and Macrophages Chapter 72: Gaucher Disease and Related Lysosomal Storage Diseases 1131

30. Brumshtein B, Salinas P, Peterson B, et al: Characterization of gene-activated human 64. Arends M, van Dussen L, Biegstraaten M, Hollak CE: Malignancies and monoclonal
acid-beta-glucosidase: Crystal structure, glycan composition, and internalization into gammopathy in Gaucher disease; a systematic review of the literature. Br J Haematol
macrophages. Glycobiology 20:24, 2010. 161:832, 2013.
31. Sawkar AR, Adamski-Werner SL, Cheng WC, et al: Gaucher disease-associated glu- 65. Becker-Cohen R, Elstein D, Abrahamov A, et al: A comprehensive assessment of renal
cocerebrosidases show mutation-dependent chemical chaperoning profiles. Chem Biol function in patients with Gaucher disease. Am J Kidney Dis 46:837, 2005.
12:1235, 2005. 66. Brady RO, Barton NW, Grabowski GA: The role of neurogenetics in Gaucher disease.
32. Ron I, Horowitz M: ER retention and degradation as the molecular basis underlying Arch Neurol 50:1212, 1993.
Gaucher disease heterogeneity. Hum Mol Genet 15:2387, 2005. 67. Harris CM, Taylor DS, Vellodi A: Ocular motor abnormalities in Gaucher disease. Neu-
33. Zimran A, Elstein D: Lipid storage diseases, in: Williams Hematology, 8th ed, edited by ropediatrics 30:289, 1999.
MA Lichtman, T Kipps, U Seligsohn, K Kaushansky, JT Prchal JT, p 1065. McGraw- 68. Uyama E, Takahashi K, Owada M, et al: Hydrocephalus, corneal opacities, deafness,
Hill, New York, 2010. valvular heart disease, deformed toes and leptomeningeal fibrous thickening in adult
34. Sidransky E: Gaucher disease: Complexity in a “simple” disorder. Mol Genet Metab 83:6, siblings: A new syndrome associated with beta-glucocerebrosidase deficiency and a
2004. mosaic population of storage cells. Acta Neurol Scand 86:407, 1992.
35. Chérin P, Sedel F, Mignot C, et al: Neurological manifestations of type 1 Gaucher’s 69. Chabas A, Cormand B, Grinberg D, et al: Unusual expression of Gaucher’s disease:
disease: Is a revision of disease classification needed? Rev Neurol (Paris) 162:1076, Cardiovascular calcifications in three sibs homozygous for the D409H mutation. J Med
2006. Genet 32:740, 1995.
36. Pandey MK, Rani R, Zhang W, et al: Immunological cell type characterization and 70. Mistry PK: Genotype/phenotype correlations in Gaucher’s disease. Lancet 346:982,
Th1-Th17 cytokine production in a mouse model of Gaucher disease. Mol Genet Metab 1995.
106:310, 2012. 71. Pastores GM, Barnett NL, Bathan P, et al: A neurological symptom survey of patients
37. Elstein D, Abrahamov A, Hadas-Halpern I, Zimran A: Gaucher’s disease. Lancet with type I Gaucher disease. J Inherit Metab Dis 26:641, 2003.
358:324, 2001. 72. Biegstraaten M, van Schaik IN, Aerts JM, Hollak CE: “Non-neuronopathic” Gaucher
38. Bohte AE, van Dussen L, Akkerman EM, et al: Liver fibrosis in type I Gaucher disease: disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of
Magnetic resonance imaging, transient elastography and parameters of iron storage. type I Gaucher disease patients and a systematic review of the literature. J Inherit Metab
PLoS One 8:e57507, 2013. Dis 31:337, 2008.
39. Xu R, Mistry P, McKenna G, Emre S, et al: Hepatocellular carcinoma in type 1 Gaucher 73. Neudorfer O, Giladi N, Elstein D, et al: Occurrence of Parkinson’s syndrome in type I
disease: A case report with review of the literature. Semin Liver Dis 25:226, 2005. Gaucher disease. Q J Med 89:691, 1996.
40. Grabowski GA: Gaucher disease and other storage disorders. Hematology Am Soc 74. Tayebi N, Callahan M, Madike V, et al: Gaucher disease and parkinsonism: A pheno-
Hematol Educ Program 2012:13, 2012. typic and genotypic characterization. Mol Genet Metab 73:313, 2001.
41. Burrow TA, Cohen MB, Bokulic R, et al: Gaucher disease: Progressive mesenteric and 75. Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R: Mutations in the glucocere-
mediastinal lymphadenopathy despite enzyme therapy. J Pediatr 150:202, 2007. brosidase gene and Parkinson’s disease in Ashkenazi Jews. N Engl J Med 351:1972, 2004.
42. Lee BH, Kim DY, Kim GH, et al: Progressive mesenteric lymphadenopathy with 76. Sidransky E, Nalls MA, Aasly JO, et al: Multicenter analysis of glucocerebrosidase muta-
protein-losing enteropathy; a devastating complication in Gaucher disease. Mol Genet tions in Parkinson’s disease. N Engl J Med 361:1651, 2009.
Metab 105:522, 2012. 77. Gan-Or Z, Giladi N, Rozovski U, et al: Genotype-phenotype correlations between GBA
43. Gillis S, Hyam E, Abrahamov A, et al: Platelet function abnormalities in Gaucher dis- mutations and Parkinson disease risk and onset. Neurology 70:2277, 2008.
ease patients. Am J Hematol 61:103, 1999. 78. Chetrit EB, Alcalay RN, Steiner-Birmanns B, et al: Phenotype in patients with Gaucher
44. Hollak CE, Levi M, Berends F, et al: Coagulation abnormalities in type 1 Gaucher dis- disease and Parkinson disease. Blood Cells Mol Dis 50:218, 2013.
ease are due to low-grade activation and can be partly restored by enzyme supplemen- 79. Alcalay RN, Dinur T, Quinn T, et al: Comparison of Parkinson risk in Ashkenazi Jewish
tation therapy. Br J Haematol 96:470, 1997. patients with Gaucher Disease and GBA heterozygotes. JAMA Neurol 71:752, 2014.
45. Zimran A, Altarescu G, Rudensky B, et al: Survey of hematological aspects of Gaucher 80. Aker M, Zimran A, Abrahamov A, et al: Abnormal neutrophil chemotaxis in Gaucher
disease. Hematology 10:151, 2005. disease. Br J Haematol 83:187, 1993.
46. Zimran A, Altarescu G, Rudensky B, et al: Survey of hematological aspects of Gaucher 81. Liel Y, Rudich A, Nagauker-Shriker O, et al: Monocyte dysfunction in patients with
disease. Hematology 10:151, 2005. Gaucher disease: Evidence for interference of glucocerebroside with superoxide gener-
47. Hughes D, Cappellini MD, Berger M, et al: Recommendations for the management of ation. Blood 83:2646-53, 1994.
the haematological and onco-haematological aspects of Gaucher disease. Br J Haematol 82. Zevin S, Abrahamov A, Hadas-Halpern I, et al: Adult-type Gaucher disease in children:
138:676, 2007. Genetics, clinical features and enzyme replacement therapy. Q J Med 86:565, 1993.
48. Poll, LW: Type I Gaucher disease: Extraosseous extension of skeletal disease. Skeletal 83. Kauli R, Zaizov R, Lazar L, et al: Delayed growth and puberty in patients with Gaucher
Radiol 29: 15, 2000. disease type 1: Natural history and effect of splenectomy and/or enzyme replacement
49. Hermann G, Shapiro R, Abdelwahab IF, et al: Extraosseous extension of Gaucher cell therapy. Isr Med Assoc J 2:158, 2000.
deposits mimicking malignancy. Skeletal Radiol 23:253, 1994. 84. Zimran A, Liphshitz I, Barchana M, et al: Incidence of malignancies among patients with
50. Kaloterakis A, Cholongitas E, Pantelis E, et al: Type I Gaucher disease with severe skel- type I Gaucher disease from a single referral clinic. Blood Cells Mol Dis 34:197, 2005.
etal destruction, extraosseous extension and monoclonal gammopathy. Am J Hematol 85. Rosenbloom BE, Weinreb NJ, Zimran A, et al: Gaucher disease and cancer incidence: A
77:377, 2004. study from the Gaucher registry. Blood 105:4569, 2005.
51. Lee RE: The pathology of Gaucher disease, in Gaucher Disease: A Century of Delineation 86. Lo SM, Choi M, Liu J, et al: Phenotype diversity in type 1 Gaucher disease: Discovering
and Research, edited by Desnick RJ, Gatt S, Grabowski GA, p 177. Alan R. Liss, New York, the genetic basis of Gaucher disease/hematologic malignancy phenotype by individual
1982. genome analysis. Blood 119:4731, 2012.
52. Amir G, Ron N: Pulmonary pathology in Gaucher’s disease. Hum Pathol 30:666, 1999. 87. Weinreb NJ, Lee RE: Causes of death due to hematological and non-hematological can-
53. Elstein D, Klutstein MW, Lahad A, et al: Echocardiographic assessment of pulmonary cers in 57 US patients with type 1 Gaucher Disease who were never treated with enzyme
hypertension in Gaucher’s disease. Lancet 351:1544, 1998. replacement therapy. Crit Rev Oncog 18(3):177, 2013.
54. Mistry PK, Sirrs S, Chan A, et al: Pulmonary hypertension in type I Gaucher’s disease: 88. Allen MJ, Myer BJ, Khokher AM, et al: Pro-inflammatory cytokines and the pathogen-
Genetic and epigenetic determinants of phenotype and response to therapy. Mol Genet esis of Gaucher’s disease: Increased release of interleukin-6 and interleukin-10. Q J Med
Metab 77:91, 2002. 90:19, 1997.
55. Rosengarten D, Abrahamov A, Nir A, et al: Outcome of ten years’ echocardiographic 89. Zimran A, Abrahamov A, Aker M, et al: Correction of neutrophil chemotaxis defect in
follow-up in children with Gaucher disease. Eur J Pediatr 166:549, 2007. patients with Gaucher disease by low-dose enzyme replacement therapy. Am J Hematol
56. Kerem E, Elstein D, Abrahamov A, et al: Pulmonary function abnormalities in type I 43:69, 1993.
Gaucher disease. Eur Respir J 9:340, 1996. 90. Zimran A, Bashkin A, Elstein D, et al: Rheological determinants in patients with
57. Itzchaki M, Lebel E, Dweck A, et al: Orthopedic considerations in Gaucher disease Gaucher disease and internal inflammation. Am J Hematol 75:190, 2004.
since the advent of enzyme replacement therapy. Acta Orthop Scand 75:641, 2004. 91. Rogowski O, Shapira I, Zimran A, et al: Automated system to detect low-grade underly-
58. Ciana G, Martini C, Leopaldi A, et al: Bone marker alterations in patients with type 1 ing inflammatory profile: Gaucher disease as a model. Blood Cells Mol Dis 34:26, 2005.
Gaucher disease. Calcif Tissue Int 72:185, 2003. 92. Boklan BF, Sawitsky A: Factor IX deficiency in Gaucher disease. An in vitro phenome-
59. Carter LC, Fischman SL, Mann J, et al: The nature and extent of jaw involvement in non. Arch Intern Med 136:489, 1976.
Gaucher disease: Observations in a series of 28 patients. Oral Surg Oral Med Oral Pathol 93. Berrebi A, Malnick SDH, Vorst EJ, et al: High incidence of factor XI deficiency in
Oral Radiol Endod 85:233, 1999. Gaucher’s disease. Am J Hematol 40:153, 1992.
60. Simchen MJ, Oz R, Shenkman B, et al: Impaired platelet function and peripartum 94. Hughes D, Cappellini MD, Berger M, et al: Recommendations for the management of
bleeding in women with Gaucher disease. Thromb Haemost 105:509, 2011. the haematological and onco-haematological aspects of Gaucher disease. Br J Haematol
61. Granovsky-Grisaru S, Belmatoug N, vom Dahl S, et al: The management of pregnancy 138:676, 2007.
in Gaucher disease. Eur J Obstet Gynecol Reprod Biol 156:3, 2011. 95. Rosenbaum H, Sidransky E: Cholelithiasis in patients with Gaucher disease. Blood Cells
62. Petrohelos M, Tricoulis D, Kotsiras I, et al: Ocular manifestations of Gaucher’s disease. Mol Dis 28:21, 2002.
Am J Ophthalmol 80:1006, 1975. 96. Ben Harosh-Katz M, Patlas M, Hadas-Halpern I, et al: Increased prevalence of
63. Wollstein G, Elstein D, Zimran A: Ocular findings in adult patients with type I Gaucher cholelithiasis in Gaucher disease: Association with splenectomy but not with gilbert
disease. Haema, J Hellen Soc Hematol 6:217, 2003. syndrome. J Clin Gastroenterol 38:586, 2004.

Kaushansky_chapter 72_p1121-1134.indd 1131 9/17/15 3:53 PM